WuXi Biologics (Cayman) Inc

02269

Company Profile

  • Business description

    WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.

  • Contact

    No. 108, Meiliang Road
    Mashan Binhu District
    Wuxi214092
    CHN

    T: +86 51085353482

    https://www.wuxibiologics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    12,552

Stocks News & Analysis

stocks

Undervalued ASX share retains wide moat rating despite regulatory pressures

Proposed price regulation impacts our fair value.
stocks

Our top ASX picks in every sector

These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks

Tesla: Shares fall as deliveries come in below consensus

Long-term growth less reliant on auto sales.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.702.000.02%
CAC 408,263.87355.134.49%
DAX 4024,007.181,085.594.74%
Dow JONES (US)47,744.671,160.212.49%
FTSE 10010,608.88260.092.51%
HKSE25,893.02776.493.09%
NASDAQ22,618.14600.292.73%
Nikkei 22556,308.422,878.865.39%
NZX 50 Index13,253.94184.281.41%
S&P 5006,766.73149.882.27%
S&P/ASX 2008,951.8021.00-0.23%
SSE Composite Index3,995.00104.832.69%

Market Movers